JULIO BELARMINO
BOBES GARCIA
Investigador hasta 2022
![Foto de JULIO BELARMINO](/img/nophoto.png)
![Foto de Hospital de la Santa Creu i Sant Pau](/img/noimage_org.png)
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (16)
2021
-
The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design
Revista de Psiquiatria y Salud Mental, Vol. 14, Núm. 3, pp. 164-176
-
The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis
Psychopharmacology, Vol. 238, Núm. 3, pp. 665-676
2020
-
Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort
Acta Psychiatrica Scandinavica, Vol. 141, Núm. 6, pp. 541-552
2019
-
Patient characteristics driving clinical utility in psychiatric pharmacogenetics: a reanalysis from the AB-GEN multicentric trial
Journal of Neural Transmission, Vol. 126, Núm. 1, pp. 95-99
2018
-
Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis
Schizophrenia Research, Vol. 193, pp. 188-196
2017
-
Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients
European Neuropsychopharmacology, Vol. 27, Núm. 7, pp. 647-656
-
Persistent negative symptoms in first-episode psychosis: Early cognitive and social functioning correlates and differences between early and adult onset
Journal of Clinical Psychiatry, Vol. 78, Núm. 9, pp. 1414-1422
2016
-
A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
International Journal of Neuropsychopharmacology, Vol. 19, Núm. 4
2014
-
Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain
Schizophrenia Research, Vol. 159, Núm. 1, pp. 107-113
2012
-
Recommendations for the prevention and management of suicidal behaviour
Revista de Psiquiatria y Salud Mental, Vol. 5, Núm. 1, pp. 8-23
2010
-
Rendimiento psicométrico de la sexta versión del Addiction Severity Index en español (ASI-6)
Psicothema, Vol. 22, Núm. 3, pp. 513-519
2009
-
Recovery from schizophrenia: Results from a 1-year follow-up observational study of patients in symptomatic remission
Schizophrenia Research, Vol. 115, Núm. 1, pp. 58-66
2008
-
The prevalence of metabolic syndrome in patients with bipolar disorder
Journal of Affective Disorders, Vol. 106, Núm. 1-2, pp. 197-201
2005
-
Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951
-
Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting
Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486
2003
-
Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481